

LONG TERM FOLLOW UP OF PERIPHERAL ARTERIAL INTERVENTION

Thesis

**Submitted for Partial Fulfillment
of MD Degree of Cardiology**

By

Ahmed Abdalla Mohamed Emam

MBBch,MSc

Under Supervision of

Professor Dr. Mohamed Ayman Saleh

Professor of Cardiology

Faculty of Medicine – Ain Shams University

Professor Dr. Ahmed Abd EL-Rahman Sharaf El-Deen

Professor of Cardiology

Faculty of Medicine – Ain Shams University

Doctor. Hamdy Soliman Mahmoud

Consultant of Cardiology

National heart institute

Doctor. Hani Mohamed Awadalla

Lecturer of Cardiology

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2010

النتائج المرتقبة طويلة المدى للعلاج التداخلي للشرايين الطرفية

رسالة

توطئة للحصول على درجة الدكتوراة في القلب والأوعية الدموية

مقدمة من

الطبيب/ أحمد عبد الله محمد إمام
ماجستير القلب والأوعية الدموية

تحت إشراف

الأستاذ الدكتور/ محمد أيمن صالح

أستاذ أمراض القلب والأوعية الدموية
كلية الطب - جامعة عين شمس

الأستاذ الدكتور/ أحمد عبد الرحمن شرف الدين

أستاذ أمراض القلب والأوعية الدموية
كلية الطب - جامعة عين شمس

الدكتور/ حمدي سليمان محمود

إستشاري أمراض القلب والأوعية الدموية
معهد القلب القومي

الدكتور/ هاني محمد عوض الله

مدرس أمراض القلب والأوعية الدموية
كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

2010

CONTENTS

	PAGE
Introduction	11
Aim of the work.....	14
Review of literature.....	15
Chapter one: Atherosclerosis pathophysiology and the Role in Peripheral Vascular Disease.....	16
Blood vessels structure and function.....	17
Atherosclerosis.....	21
Chapter two: Peripheral Arterial Disease: Diagnosis and Management.....	46
Risk factors.....	48
Clinical features.....	52
Intermittent claudication.....	54
Critical limb ischemia.....	55
Diagnosis.....	56
Treatment	59
Specific drug therapy for PAD.....	62
Chapter three: Endovascular therapies for peripheral arterial disease.....	66
Patient Selection and Outcomes.....	68

CONTENTS_(CONT.)

	PAGE
Aorto-iliac Disease.....	68
Common and Deep Femoral Artery Disease.....	75
SFA and Popliteal Artery Disease.....	78
Brachytherapy.....	81
Debulking Strategies.....	83
Cryoplasty.....	84
Cutting-Balloon Angioplasty.....	85
Drug-Eluting Balloons and Stents.....	85
Covered Stents.....	86
Tibial and Peroneal Artery Disease.....	88
Drug-Eluting Stents.....	90
Angiogenesis.....	91
Patients and methods.....	93
Methods of the study.....	95
Twelve months follow up.....	100
Data management and analysis.....	102
Results.....	103

CONTENTS_(CONT.)

	PAGE
Discussion.....	126
Conclusion.....	142
Recommendation.....	144
References.....	146
Summary.....	201
Arabic summary.....	207

LIST OF TABLES

TABLE NO.	PAGE
Table 1. Classification of PAD: Fontaine's Stages and Rutherford's Categories	55
Table 2. Disease Severity and Ankle-Brachial Index (ABI) (Mayo clinic Vascular Laboratory Criteria.....	57
Table 3. Modified TASC Morphological Classification of Iliac Lesions	72
Table 4. Modified TASC Morphological Classification of Femoral-popliteal Lesions.....	79
Table 5. Baseline characteristics of the patients and treated Lesions.....	105
Table 6. Immediate and in-hospital results.....	107
Table 7. Balloons and stents, numbers and size.....	108
Table 8. Factors affecting the immediate and in-hospital Mortality.....	109
Table 9. Factors affecting the immediate and in-hospital Morbidity.....	110
Table 10. Diabetes mellitus and its relation with in hospital mortality and morbidity.....	111
Table 11. One year follow up results.....	113
Table 12. Factors affecting one year outcome results.....	114
Table 13. Relation between the single and bilateral LL Affection.....	115
Table 14: Comparison between the single and bilateral LL lesions.....	116

LIST OF TABLES_(CONT.)

TABLE NO.	PAGE
\	
Table 15: Comparison between diabetics and non diabetic patients.....	117
Table 16: Comparison between diabetics and non diabetic patients.....	118
Table 17: Relations of procedure success.....	119
Table 18: Comparison between procedure success and failure.....	120
Table 19: Relations of lower limb symptoms recurrence with different factors.....	122
Table 20: Factors that influence recurrence of symptoms one year following the intervention.....	123
Table 19: Comparison and relations of different sites of lesions.....	124

LIST OF FIGURES

FIGURE NO.	PAGE
Figure. 1. Initiation of atherosclerosis.....	28
Figure. 2. Inflammation links classic risk factors to altered cellular behavior within the arterial wall and secretion of inflammatory markers in the circulation.....	31
Figure. 3. Progression of atherosclerosis.....	33
Figure. 4. Thrombotic complication of atherosclerosis.....	36
Figure 5. Risk of developing lower extremity peripheral arterial disease.....	49
Figure 6. Algorithm for evaluating patients in whom peripheral arterial disease is suspected.....	53
Figure 7. A, Distal aorta severe stenosis .B, after treatment with balloon-expandable stent.....	69
Figure 8. Baseline angiography of TASC D lesion	70
Figure 9. Left, Baseline angiography of tandem critical lesions of the deep femoral (profunda femoris) artery. Right, Endovascular profundaplasty after balloon Angioplasty.....	77
Figure 10. Data from randomized trial of SFA lesions showing superiority for stent over balloon angioplasty at 1 year for maximal distance walked and ABI.....	80
Figure 11. Kaplan–Meier plot of cumulative recurrence rate after femoro-popliteal balloon angioplasty compared with angioplasty with Brachytherapy showing no difference.....	82

LIST OF FIGURES_(CONT.)

FIGURE NO.	PAGE
Figure 12. A, Angiogram of a tibio-peroneal artery stenosis . B, Final angiogram after treatment with a coronary balloon-expandable stent.....	89
Figure 13: Intervention success rate.....	106
Figure 14: One year follow up patients state.....	106

LIST OF ABBREVIATIONS

ABI = Ankle-brachial index.
ACC = American College of Cardiology
ACE = Angiotensin-converting enzyme.
ACS= Acute coronary syndromes.
AHA = American Heart Association.
Apo C-III= Apolipoprotein C-III.
CAPRIE =Clopidogrel versus Aspirin in Patients at
Risk of Ischemic Events.
CFA=Common femoral artery.
CLEVER= Claudication: Exercise Versus Endoluminal
Revascularization.
CLI = Critical limb ischemia
COPD = Chronic obstructive pulmonary disease
CTA = Computed tomographic angiography
DNA = Deoxyribonucleic acid.
DIC=Disseminated intra vascular coagulopathy.
DP =Dorsalis pedis.
FDA = Food and Drug Administration
HDL = High-density lipoprotein
HMG = Hydroxymethyl glutaryl.
IC= Intermittent claudication.
ICAM-1= Intercellular adhesion molecule-1
INR = International normalized ratio
LDL = Low-density lipoprotein
Lipoprotein (a)= Lp [a]
MI = Myocardial infarction
MRA = Magnetic resonance angiography.
NF- α =Tumor necrosis factor- α .
NF- κ B=Nuclear factor- κ B .
NO=Nitric oxide.
OR = odds ratio.

LIST OF ABBREVIATIONS (CONT.)

Ox-LDL= Oxidized LDL.

P = statistical significance

PAD = peripheral arterial disease.

PAI-1=plasminogen activator inhibitor-1.

PDGF =platelet-derived growth factor.

PPAR- α =Peroxisome proliferator-activated receptor- α .

PT= posterior tibial

PTA = percutaneous trans-luminal angioplasty.

PVD=Peripheral vascular disease.

SFA= Superficial femoral artery.

SMC=Smooth muscle cells.

Std. Deviation: Standard deviation.

TASC = Trans Atlantic Inter-Society Consensus Working Group.

TGF- β = Transforming growth factor- β

TIA = Transient ischemic attack.

TRLPs = Triglyceride-rich lipoproteins.

VCAM-1=Vascular cell adhesion molecule-1.

VLDL=Very low density lipoprotein.

Acknowledgement

*First of all, thanks to **Allah** who granted me the ability to accomplish this work.*

*Words can never express my deepest gratitude and sincere appreciation to **Prof. Dr. Ayman saleh**, Professor of Cardiology, Faculty of Medicine, Ain Shams University, for his continuous encouragement, excellent guidance, powerful support, extreme patience and faithfully advice. I really had the honor of having his supervise for this work.*

*My deepest thanks, appreciation and sincerest gratitude to **Prof.Dr. Ahmed Abd El-Rahman**, professor of Cardiology, Faculty of Medicine, Ain Shams University, who spared no time and effort to provide me with her valuable instructions and his expert touches. his wise supervision gave me invaluable opportunity to benefit from his faithful guidance and continuous support.*

*My everlasting gratitude to **Dr.Hamdy Soliman**, consultant cardiologist, national heart institute, for his great help, continuous guidance and for offering me much of his time and effort. His extreme careful supervision and precise advices are more that I can express.*

*My ever tanks to **Dr.Hany Awad Allah**, assistant professor of Cardiology, Faculty of Medicine, Ain Shams University, for his always help, continuous advices and for giving me much of his time and effort.*

*Finally, my truthful affection and love to my parents,wife,**SON** who were, and will always be, by my side, all my life.*



Introduction and Aim of the Work



INTRODUCTION

Peripheral arterial disease (PAD) is one manifestation of systemic atherosclerosis. The prevalence of PAD increases with the age of the population.^{1,2} It is important to remember the significant association of coincident coronary artery disease and cerebrovascular disease in these patients, because it represents the major cause of major morbidity and mortality in the PAD population.³ Remarkable technological advances in the past decade, along with patient preference, have shifted revascularization strategies from traditional open surgical approaches toward lower-morbidity percutaneous endovascular treatments. Catheter-based revascularization of the lower extremities was first performed by Charles Dotter⁴ and advanced by Andreas Gruentzig, who employed then newly developed inflatable balloon catheters that could dilate vascular stenosis.⁵ The availability of stents, more than any other advance, has fueled the growth of catheter-based procedures by improving the safety, durability, and predictability of percutaneous revascularization.

Endovascular therapy offers several distinct advantages over open surgical revascularization for selected lesions.^{6,7} It is performed with local



anesthesia, which enables the treatment of patients who are at high risk for general anesthesia. The morbidity and mortality from catheter-based therapy is extremely low, especially compared with open surgical revascularization. After successful percutaneous revascularization, patients are ambulatory on the day of treatment, and unlike after vascular surgery, they can often return to normal activity within 24 to 48 hours of an uncomplicated procedure. Endovascular therapies generally do not preclude or alter subsequent surgery and may be repeated if necessary.

Multiple specialties, including interventional cardiology, have contributed to the advancement of the field of peripheral vascular intervention over the past several decades.⁸ The recognition of an unmet need for a trained cadre of clinicians to care for patients with PAD prompted the development of a core curriculum document (COCATS-11)⁹ and a multispecialty societal competency statement.¹⁰ The American Heart Association and American College of Cardiology have published guidelines and recommendations for the diagnosis and treatment of PAD.² Improved patient and physician awareness of PAD and the availability of high-quality noninvasive diagnostic imaging have increased the number of patients seeking treatment for PAD.